AlphaNet is proud to work with the providers of the four augmentation therapy products approved by the U.S. Food and Drug Administration (FDA). The four products are Prolastin-C® from Grifols, Zemaira® from CSL Behring and Aralast NP™ and Glassia® from Shire.
What is the primary purpose of augmentation therapy?
Augmentation therapy is intended to augment (add to) the amount of alpha-1 antitrypsin protein (AAT) floating in the blood and bathing the tissues of the body in people with lung disease related to Alpha-1.
Although some people report that they notice improvements in their health when on augmentation therapy, and there is some evidence for a decrease in the number of lung infections in individuals receiving augmentation therapy, the primary aim of this therapy is to reduce the rate of decline of lung function towards normal and, therefore, improve the long-term quality of life and even the lifespan of those with lung disease due to Alpha-1.
Everyone loses lung function during their adult life, whether they have Alpha-1 or not. Alphas with lung disease lose their lung function at a more rapid rate than normal. If augmentation therapy is effective, it will be expected to slow this increased rate of decline, regardless of the severity of the underlying lung disease.
For more information on click on the Augmentation Therapy Skinny Little Reference Guide.